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Summary Background: Studies into the effects of salbutamol in the treatment of
wheeze in infancy have been conflicting, possibly due to differences in outcome
variables. We aimed to assess the response to salbutamol using indices derived from
passive and forced expiration.
Methods: We recruited 39 infants who had a history of wheezing (mean age 43
weeks) and measured maximum flow at functional residual capacity (V 0max FRC) by
rapid thoracoabdominal compression (RTC), and forced expired volume at 0.4 s
(FEV0.4) using the raised-volume RTC technique (RV-RTC). We calculated passive
compliance (Crs), resistance (Rrs) and time constant (t) from relaxed expirations that
followed the augmented inspirations delivered during RV-RTC. Measurements were
repeated after aerosol salbutamol (800mcg).
Results: Data were obtained in 32 infants for V 0max FRC; 22 for FEV0.4 and 19 for
passive mechanics. There were no mean changes in any index of forced expiration
after salbutamol. Some individuals showed significant changes (improvement or
worsening) in one or other index. Overall, there was a small increase in Crs after
salbutamol but no change in Rrs or t:
Conclusions: We found no consistent pattern of response in either index of forced
expiration. Validated clinical scores or alternative physiological techniques may be
preferable to respiratory mechanics in assessing bronchodilator response.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Up to 40% of infants experience wheeze in the first
year of life.1 Many are treated with b-2 agonists,
although studies examining their effectiveness in
wheezing infants in hospital2–7 and in domiciliary
settings8 are conflicting. The reasons for these
conflicting findings may relate to differences in
study populations, the underlying pathology, the
severity of airflow obstruction, the dose adminis-
tered, methodology employed and the outcome
techniques used to measure a response.
One of the most commonly employed experi-
mental methods for assessing changes in respira-
tory function is the rapid thoracoabdominal com-
pression (RTC) technique, from which maximum
flow at functional residual capacity (V 0max FRC) is
measured.2–7 This measurement has considerable
inter-subject variability and is influenced by
changes in FRC that may accompany effective
bronchodilatation,9 potentially reducing its sensi-
tivity to detect any response. Its reproducibility
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has, however, been shown to be similar to
spirometry in adults.10 The technique of raised-
volume RTC (RV-RTC) permits recording of timed
expired volumes, avoiding the need for a fixed
volume landmark and mimicking spirometric mea-
surements in older subjects.11 RV-RTC has been
shown to be more reproducible than V 0max FRC:
12,13
Despite the application of these and other
techniques, controversy still surrounds the effec-
tiveness of b-2 agonists in improving lung function.
Some studies have shown an improvement in lung
function in response to salbutamol,14 others
suggested that there was a worsening,2,3,7,15 while
some failed to demonstrate a significant change,5,8,16
or showed changes in some subjects4,10 or certain
parameters.6,17 Methodological issues could underlie
these discrepant findings, and so the aim of this
study was to compare different methods of asses-
sing airway function in wheezy infants given a
standard dose of salbutamol in a laboratory setting.
We chose to include both RTC and RV-RTC. Because
the technique of RV-RTC involves a series of
augmented inspirations that (apart from the last)
are followed by passive expirations, passive lung
mechanics can also be calculated. This comprised
our third method of assessing the response in
our study, whose aim was to determine the
short-term response of wheezy infants to aerosol
salbutamol, using several different physiological
techniques.
Methods
Subjects
Power calculations performed at the outset indi-
cated that a difference of 1 standard deviation in
the measurement of V 0max FRC; significant at the 5%
level, could be detected with a power of 81% if the
study group comprised 32 infants. We recruited 39
infants to allow for occasions when the infant did
not sleep well enough for us to collect sufficient
data. They were aged 3–15 months, with a history
of wheezing requiring either hospital admission or a
period of medication lasting at least 6 weeks.
Infants with other specific disorders of the respira-
tory or cardiovascular systems were excluded.
Approval from the local Research Ethics Committee
and written parental consent were obtained. At the
time of the investigation, three of the infants were
noted to be slightly wheezy. Sixteen of the infants
were not on any medications and four were on
ipratropium bromide alone. The remainder were
taking inhaled steroids alone (five infants), b-2
agonists alone (six infants) or a combination of both
(eight infants).
Protocol
Infants attended the laboratory as outpatients. A
brief questionnaire was administered, an explana-
tion of the procedure was given to the parents and
the infant was examined. Baseline oxygen satura-
tion was recorded and the infant was sedated with
chloral hydrate (100mg kg1 body weight, up to a
maximum dose of 1 g). A pulse oximeter (Nellcor)
was attached to the foot for safety and pulse rate
monitoring.
Rapid thoracoabdominal compression
The infant was wrapped in an inflatable ‘squeeze’
jacket and breathed through a facemask (Rendell
Baker size 2) and pneumotachograph (Jaeger infant
model). Three signals (mask pressure, flow and
jacket pressure) were recorded onto a personal
computer (Elonex) with specialist software (RASP,
Physiologic, Newbury, Berks). A period of regular
breathing of approximately 20 s was observed
prior to inflating the jacket at the end of a tidal
inspiration.18 Measurements of V 0max FRC were re-
peated over a range of jacket pressures up to a
maximum of 6.5 kPa to obtain the highest values of
V 0max FRC and the pressure at which this was achieved
(the optimal pressure) was noted for each infant.
Several measurements were obtained at optimal
pressure.
Raised-volume rapid thoracoabdominal
compression
A bias flow of air was attached to the pneumota-
chograph using a T-piece attached to an adjustable
blow-off valve set at 2.0 kPa. Augmented breaths
were delivered through the facemask by manually
occluding the bias flow at the onset of inspiration so
that air was directed into the lungs. At the end of
inspiration (when the applied pressure and volume
reached plateaux) the occlusion was removed and
the infant breathed out passively. A series of four
successive augmented inspirations were delivered
with passive exhalations, followed by a fifth
augmented inspiration, which was accompanied
by jacket inflation at the end of inspiration using
the previously determined optimal jacket pressure.
Up to six measurements of RV-RTC were made in
each infant.
The infant was then given salbutamol (Ventolin,
Glaxo Smith Kline) 800mcg by metered dose
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inhaler, spacer (Babyhaler, Glaxo Smith Kline), and
facemask (Laerdal size 2, Laerdal, Norway). All
measurements were repeated 15min after the
salbutamol administration. Pulse rate was recorded
every minute from the pulse oximeter, starting
immediately before administration of salbutamol
and continuing for 15min afterwards.
Analysis
Measurements of V 0max FRC were classed as techni-
cally satisfactory if a clearly defined peak flow was
seen early in the breath (before 33% of the previous
tidal volume had been exhaled) and if expiration
proceeded smoothly beyond resting end-expiratory
volume. V 0max FRC was recorded as the highest value
from a technically satisfactory manoeuvre, pro-
vided that a second measurement was within 10% of
the best value, and also as the mean of the highest
four values.
Measurements of RV-RTC (Fig. 1) were analysed
using specialist software (‘Squeeze’ version 2.04,
Dixon and Stocks, Imperial College, London, 1999),
using a published technique.12 The first augmented
breath was excluded from analysis, then remaining
augmented breaths were inspected and the passive
flow–volume relationship characterised by linear
regression analysis to determine the elastic equili-
brium volume (EEV), by extrapolation of the
regression to the volume axis.
The slope of the regression line through the
linear portion of the passive expiration was the
time constant of the respiratory system, t: Com-
pliance of the respiratory system (Crs) was derived
from the measured applied inflation pressure and
the difference between inflation volume and EEV,
and resistance of the respiratory system (Rrs) from
t ¼ CrsRrs: The mean values of t; Crs and Rrs for each
infant were based on all acceptable passive
expirations.
The forced expired volume in the first 0.4 s of
expiration (FEV0.4) was measured from the RV-RTC
and the highest individual value reported.
Statistical analysis
For each index (V 0max FRC; t; Crs; Rrs and FEV0.4) the
values obtained before and after salbutamol were
compared by paired t-test. In order to see whether
any changes in FEV0.4 related to the baseline
measurement, we performed a regression analysis
of the absolute change against the baseline value.
For every infant, the standard deviation of each
index was calculated from baseline measurements.
A change in the measurement of 2 SD or more
following salbutamol was taken as a significant
difference for that infant.
Paired t-tests were used to establish whether
there were any significant associations between
indices of forced expiration and Crs:
Results
Infants attended at a mean (SD) age of 43(18.8)
weeks, weight of 9.5(1.8) kg, and length of
73.2(6.4) cm. The median (range) number of
hospital admissions was 1 (0–10). Only one infant
never had a hospital admission. Three infants had
mild wheeze at the time of the appointment but
were otherwise well. Sixteen received regular
inhaled medications (10 inhaled corticosteroids
(ICS) alone, one b-2 agonist alone, three a
combination of ICS and b-2 agonist, and two
ipratropium bromide). Eighteen of the infants had
a family history of asthma in a first-degree relative.
Mean baseline oxygen saturation was 96.9% and
the minimum saturation after salbutamol was 92.4
(SD 2.7)%.
Satisfactory paired measurements before and
after salbutamol were obtained in 32 infants for
V 0max FRC; 22 for FEV0.4, and 19 for t; Crs; and Rrs:
Sometimes the infant woke before completion of
measurements and on some occasions technically
satisfactory measurements were not obtained. In
16 infants the response could be determined for all
three indices of responsiveness.
Confirmation that a physiologically active dose of
salbutamol had been given was noted from the
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Figure 1 Example of flow volume loops from one infant
showing three manoeuvres, each with an augmented
inspiration with passive expiration and the subsequent
augmented inspiration with forced expiration. The three
manoeuvres have been overlaid and aligned at the EEV.
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mean increase in heart rate of 21%. The increase
was at least 10% in all but two infants.
There were no differences in the mean jacket
inflation pressures and pressure applied at the
airway opening during RV-RTC before and after
salbutamol (Table 1).
Indices of forced expiration
Baseline V 0max FRC was below the predicted value
19 in
most infants (mean (SD) score¼2.17 (1.05)).
There was no response to salbutamol in terms of
mean changes in V 0max FRC or FEV0.4 (Table 2).
However, some infants showed considerable change
in one or more of these measurements (Fig. 2). Of
16 infants in whom the response could be deter-
mined for all three indices of responsiveness, one
showed no response in any index, six showed an
improvement in at least one index and another six
demonstrated a worsening of function, and the
remaining three infants had a mixed pattern with
apparent worsening of one index and improvement
in another. Patterns of response were unrelated to
family history of asthma. The overall pattern of
response showed that changes were most likely to
be seen in FEV0.4 and least likely to be seen in
V 0max FRC (Fig. 3). Changes in FEV0.4 were unrelated
to the baseline value (data not shown).
The baseline coefficient of variation (the SD
expressed as a percentage of the mean baseline
values) was smaller for FEV0.4, (mean (SD)
4.0(1.90)%) than for V 0max FRC (10.4(4.9)%).
Indices of passive mechanics
The mean (SD) number of passive expirations on
which passive mechanics was based was 5.2 (1.7).
Overall, there was a small but statistically significant
increase in respiratory system compliance after
salbutamol without any evidence of change in t or
Rrs (Table 3). When statistically significant individual
changes (based on 2 SD) were examined, four infants
showed an increase in compliance and the remainder
showed no change. Rrs increased in three infants and
decreased in four, and t increased in five and
decreased in one infant. There was no consistency
between change in any index of passive mechanics
and any index of forced expiration. The changes in
passive mechanics were unrelated to family history of
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Table 1 Applied pressures.
RTC baseline RTC post-salbutamol RV-RTC baseline RV-RTC post-salbutamol
Pj (kPa) 3.51 (0.16) 3.62 (0.21) 3.53 (0.18) 3.82 (0.24)
Pinf (kPa) 1.79 (0.128) 1.82 (0.125)
PjFlowest pressure used to inflate jacket to achieve one of the four best values of V 0max FRC:
PinfFpressure applied to the airway opening during RV-RTC. Values are mean and standard deviation.
Figure 2 Individual changes in V 0max FRC and FEV0.4.
Table 2 Forced expiratory indices.
n Baseline
mean (SD)
Post-salbutamol
mean (SD)
Mean
difference
95% CI of
difference
Maximal V 0max FRC (ml s
1) 32 133 (76.3) 135.7 (77.3) 2.3 8.9, 13.5
Mean V 0max FRC (ml s
1) 28 117.3 (74.9) 125.4 (78.0) 8.1 1.9, 18.1
FEV0.4 (ml) 22 139 (31.7) 142.1 (37.2) 3.1 5.7, 11.9
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asthma. Our finding that there was a significant
increase in Crs led us to speculate that the infants
with the greatest changes in Crs might be those who
demonstrated significant changes in forced expira-
tion, but there was no evidence of any significant
association between V 0max FRC or FEV0.4 and Crs (data
not shown) (P ¼ 0:54 and 0.10, respectively).
Discussion
For the group of wheezy infants as a whole, we
failed to demonstrate a consistent physiological
response to salbutamol using any index of forced
expiration derived from the standard or raised-
volume RTC. This was in spite of the fact that all
except three infants had a negative SD score for
V 0max FRC; implying that they had the likely potential
to improve their lung function from baseline. A
minority of infants showed individual significant
changes in lung function that usually consisted of
an increase but occasionally a worsening of flow,
during a single study.
Individual responses in V 0max FRC were defined as a
change of 72SD from baseline. An alternative
approach for assigning a significant change has
been proposed, based on the 95% confidence
interval of repeated measurements.10 In this
approach a change of 27% from baseline would be
significant. Had we adopted this method there
would have been no substantive change in our
findings; four infants who we considered to have a
worsening of V 0max FRC after salbutamol would have
been reclassified as non-responders.
The lack of consistent findings in previous
reports2–8,14–17 may result from (i) differences in
the age or underlying pathology of the infants,
which could affect the nature of response to
bronchodilator, (ii) differences in the dose and
delivery system for administering b-2 agonists, and
(iii) differences in the physiological outcome vari-
ables examined. Although the dose and delivery
system has varied between studies, an increase in
heart rate has usually indicated that a physiologi-
cally active dose has been absorbed, so it seems
unlikely that this could have made a major
contribution to differences in lung mechanics.
Differences in the populations of infants
tested
Most investigations have included infants with an
age range spanning many months. Some have
included predominantly younger infants (under 6
months) with bronchiolitis, studied before hospital
discharge,4,17 whereas others have looked at older
infants in a symptom-free interval.16 Variation in
the clinical status will affect the outcome as the
degree of airway obstruction may influence both
the effective dose delivered to the airway and the
likelihood of detecting a response. Furthermore,
the predominant causes of obstruction (contraction
of airway smooth muscle, inflammation or mucus
secretion) will affect the response to bronchodi-
lator. There does not appear to be a consistent
finding related to age, apart from one report in which
infants aged below 3 years were studied and those
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Table 3 Passive mechanics (n ¼ 19).n
Baseline mean Post-salbutamol mean Mean difference (%) 95% CI of difference
Crs (ml cm H2O
1) 88.2 92.8 4.56 (5.89) 1.59, 7.53*
Rrs (cm H2O l
1 s) 5.76 5.88 0.12 (2.08) 1.04, 0.78
t 0.484 0.512 0.0278 0.082, 0.027
nrepresents significant change after salbutamol.
Positive Response to Salbutamol 
Negative Response to Salbutamol 
FEV0.4V’maxFRC
FEV0.4V’maxFRC
Figure 3 Distribution of responses in indices of forced
expiration in five infants with a positive response to
salbutamol and six with a negative response. Data are not
shown for the infants with no significant changes in any
index or with mixed responses.
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found to respond were all under 1 year.20 Similarly,
some reports have included infants with a diagnosis of
RSV-positive bronchiolitis3,4,6 whereas others have
involved infants with documented wheeze and
tendency to atopy,8 and others have included all
infants with wheezing.5,16 There is no clear pattern of
measurable improvement in response to bronchodi-
lator relating to the population of infants under
study. In the current report there was no evidence of
any relationship between a family history of asthma
and responsiveness to bronchodilator. A recent
consensus review concluded that there was no
compelling evidence for use of bronchodilators in
the management of bronchiolitis,21 although they
may produce modest short-term improvements in
clinical scores.22 Similarly, it would appear that there
is no clear benefit of using b-2 agonists to treat
recurrent wheeze in the first 2 years of life.23
Differences in outcome variables
The issue of how to measure and interpret possible
changes in respiratory function in response to
salbutamol has been longstanding. Historically,
changes in measurements of lung volume and
airway resistance were used.14 The introduction
of RTC enabled investigators to measure V 0max FRC;
which is thought to be pressure-independent and
therefore to reflect changes in intrathoracic airway
function and more closely resemble the spirometric
indices used in older subjects. Given apparent
clinical improvements in wheezy infants following
administration of salbutamol,24 it was surprising
that early studies showed a fall in forced flows after
salbutamol.2,3 Nevertheless, using V 0max FRC this
group showed that pre-treatment with salbutamol
protected against histamine-induced bronchocon-
striction,25 indicating the presence of functional
b-2 receptors. Subsequently four studies have
sought statistically significant changes in V 0max FRC
in individual wheezy infants, three of which showed
variable responses,4,8,10 whereas the other failed to
identify any infant in whom V 0max FRC improved.
6
The limitations of the RTC technique relate
mainly to the variability of end-expiratory level
(EEL).9 Interventions that change EEL, such as
spontaneous changes in respiratory rate, can alter
V 0max FRC: Hence RV-RTC was developed so that
indices independent of EEL could be explored. The
variability of measurements derived from RV-RTC
has been reported to be less than V 0max FRC in some
studies12,13,26 but greater in others.27 They were
found to be better able to detect early changes in
lung function in infants with cystic fibrosis.11,28
Despite this, in a group of wheezing infants who
were asymptomatic at testing there were no
significant changes in response to salbutamol5 and
this observation led us to restrict our analysis of RV-
RTC parameters to the timed volume FEV0.4.
A range of different parameters can be analysed
from RV-RTC. These include the volume expired,
often referred to as forced vital capacity (although
the manoeuvre neither begins at total lung capacity
nor finishes at residual volume) and the timed
volumes (FEV0.75, FEV0.4, etc.), all of which will be
sensitive to inflation pressure. Moreover, since
measurements of infant lung function are probably
mainly made during nose breathing, flows at high
lung volumes could be limited by nasal dimensions
and nasal airway resistance rather than by the
intrathoracic airways, as demonstrated in older
children29 and adults.30 Flows that are early in the
breath and therefore close to peak flow will be
particularly affected. Similarly, the shorter-timed
volumes will be disproportionally affected when
compared with the longer-timed volumes such as
FEV0.75. Unless severe, nasal obstruction does not
affect maximum flow at low volumes.31 Any fixed,
nasal limitation to flow would be expected to
reduce variability in timed volumes, and the least-
variable index in the current study was indeed
FEV0.4. The small coefficient of variation may
explain why this particular index was the one most
likely to show significant changes in individuals.
The lack of group differences in indices of forced
expiration after salbutamol (although individual
infants appeared to respond), suggests that
either these indices are not suitable for describing
the effects of salbutamol or that the response is not
consistent between infants. Passive mechanics (Crs;
Rrs) should not be influenced by inflation pressure in
the same way as indices of forced expiration. We
found a small but significant increase in compliance
following salbutamol. This contrasts with the
findings of Hughes et al.3 who found no differences
in Crs; Rrs; or t in response to salbutamol, and
Chavasse et al.8 who found an increase in Rrs and a
trend towards an increase in Crs and respiratory
rate. However, the infants in these studies did not
receive augmented inspirations and passive me-
chanics were measured by occluding the airway at
the end of tidal inspiration. By augmenting inspira-
tion, we were able to measure t over an extended
volume range. Our findings suggest that the
respiratory system became less stiff in response
to salbutamol, but we were unable to demonstrate
any change in Rrs that could indicate altered airway
dimensions. Furthermore, individual changes in
passive mechanics were unrelated to changes in
any index of forced expiration. Changes in airway
mechanics in response to bronchodilators or
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bronchoconstrictors are complex,32 with changes in
airway calibre and elastance influencing forced
expiratory flow in opposing directions. This poses a
problem for those interested in investigating the
pathophysiology of wheezing disorders. Ausculta-
tion has been used in the investigation of bronch-
oconstriction in small children undergoing
methacholine challenge,33 with the detection of
wheeze being the endpoint of the challenge. The
diminished airway potency observed in infants with
transient wheeze1 has been assumed to support this
as a practical method for detecting reduction in
airway calibre. The response to bronchodilator
involves an increase in airway compliance,34 which
may diminish flow both by reduction in the speed of
wave propagation and by an increase in dynamic
compression.35 The point at which any increase in
airway diameter overrides the alterations in com-
pliance is not clear, but a combination of measure-
ments of high-frequency input impedance36 with
more classical techniques of lung function may
gradually increase our understanding of underlying
changes in airway physiology.
Conclusions
Although there are limited data testifying to the
clinical effectiveness of salbutamol in the treat-
ment of infants with wheezing, we have been
unable to demonstrate a consistent pattern of
response, despite looking at V 0max FRC; derived from
RTC, one timed volume (FEV0.4) from RV-RTC, and
passive lung mechanics (Rrs and Crs). Even in infants
with some evidence of response to salbutamol,
there was inconsistency between physiological
outcomes, raising doubts about the validity of the
responses. Thus it seems probable that (i) our tests
of lung function cannot detect subtle changes
brought about by bronchodilators or (ii) individual
infants respond in different ways and these are
masked by studies of groups of infants with varying
underlying pathology7 or (iii) there were no
beneficial effects of bronchodilator in these pa-
tients. Investigation of individual patients and
groups should perhaps revert to validated clinical
scores, while groups of subjects should be placed in
well-characterised phenotypes before study.
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